Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England

BMJ. 2001 Mar 17;322(7287):651-2. doi: 10.1136/bmj.322.7287.651.

Authors

S A Shakir¹, L V Wilton, A Boshier, D Layton, E Heeley

Affiliation

¹ Drug Safety Research Unit, Bursledon Hall, Southampton SO31 1AA. saad.shakir@dsru.org

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
Adolescent
Adult
Aged
Aged, 80 and over
Cardiovascular Diseases / chemically induced*
Cardiovascular Diseases / mortality
Cause of Death
Drug Prescriptions
England / epidemiology
Erectile Dysfunction / drug therapy
Follow-Up Studies
Humans
Male
Middle Aged
Phosphodiesterase Inhibitors / adverse effects*
Phosphodiesterase Inhibitors / therapeutic use
Piperazines / adverse effects*
Piperazines / therapeutic use
Purines
Sildenafil Citrate
Sulfones
Survival Rate

Substances

Phosphodiesterase Inhibitors
Piperazines
Purines
Sulfones
Sildenafil Citrate
3',5'-Cyclic-GMP Phosphodiesterases